Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors ...

Shares of Pfizer are down 50% from their 2021 high, and the yield is an alluring 6.4%.

Quick Read Pfizer (PFE) posted Q4 adjusted EPS of $0.66 beating the $0.57 consensus on $17.56B in revenue while its non-COVID ...

Q1 earnings May 4: analyst EPS/revenue estimates, 2026 guidance focus, oncology & obesity pipeline catalysts, and cost cuts.

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Veppanu, the first PROTAC therapy approved by the FDA, improved progression free survival by 43% versus AstraZeneca’s ...

Hey, can Pfizer break out of its multi-year rut? Now, a lot depends on the presentation because I haven’t seen any needle ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer and Arvinas are poised to bring the third oral selective oestrogen receptor degrader (SERD) to market in the US, after ...

Lyme disease is the most common tick-borne infectious disease in the United States. There is no vaccine to protect against it in humans. Biopharmaceutical company Pfizer and Valne ...